1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments

REPORT HIGHLIGHTS

The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a compound annual growth rate (CAGR) of 12.4% from 2014 to 2019.

This report provides:

An overview of the global diabetes treatment market.
Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.
Information on the field of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors collectively known as incretin-based therapies, a drug category used mainly for the control of diabetes but that also have potential indications for cardiovascular treatment and even weight loss.
Drug sales earned according to therapeutic area as well as by geography.
Analysis of the market's dynamics, specifically major issues, and challenges.
Relevant intellectual property (IP) and patent analysis.

SCOPE OF REPORT

The scope of this study encompasses companies that are involved in diabetes prevention as well as detection, diagnosis and treatment. BCC Research analyzes each technology or therapy type, determines its current market status, examines its impact on future markets and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.

Table Of Contents

Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments

Chapter- 1: INTRODUCTION - Complimentary 3

STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THIS STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER

Chapter- 2: EXECUTIVE SUMMARY 8

INCRETINS FILL NEED FOR GLYCEMIC CONTROL
TRENDS IN DISPENSING AND SALES
GEOGRAPHICAL SHIFTS
KEY DRIVERS
KEY CHALLENGES
KEY TRENDS

Chapter- 3: OVERVIEW AND MARKET FORECAST 45

DATA ON WHERE INCRETINS FIT
FOR SOME, A GLP-1 FOCUS
STANDARD DIABETIC TREATMENTS
DIABETES FURTHER EXPLAINED
INCRETIN THERAPIES
MARKET LANDSCAPE
DEALS IN THE INCRETIN MARKET
Figure 1 : THE INCRETIN EFFECT ILLUSTRATED
Figure 2 : PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR NON-INSULIN ANTIDIABETICS, 2012

Chapter- 4: THE DEVELOPMENT PIPELINE 33

REGULATORY ENVIRONMENT
PATENTS
DEVELOPMENT PIPELINE
DEVELOPMENT CASE STUDY: PHENOMIX
PROMISING PIPELINE CANDIDATES AND NOVEL RESEARCH
DEVELOPMENT LANDSCAPE: OVERALL PHARMA MARKET

Chapter- 5: COMPANY PROFILES 47

ACTIVX BIOSCIENCES INC. (KYORIN PHARMACEUTICAL CO. LTD.)
AERPIO THERAPEUTICS INC.
AMPIO PHARMACEUTICALS INC.
AMUNIX
ARAIM PHARMACEUTICALS INC.
ARISAPH
ASTRAZENECA
BECTON, DICKINSON AND COMPANY
BOEHRINGER INGELHEIM GMBH
BRISTOL-MYERS SQUIBB
CEBIX INC.
CHEMOCENTRYX INC.
CODA THERAPEUTICS INC.
CONCERT PHARMACEUTICALS
CONJUCHEM
DIPEXIUM PHARMACEUTICALS INC.
DONG-A SOCIO HOLDINGS
ELI LILLY AND COMPANY
EMISPHERE TECHNOLOGIES INC.
EVOKE PHARMA INC.
FURIEX PHARMACEUTICALS INC.
GENKYOTEX S.A.
GLAXOSMITHKLINE PLC
GLYCADIA PHARMACEUTICALS
HANMI PHARMACEUTICAL CO. LTD.
ICO THERAPEUTICS INC.
INTARCIA THERAPEUTICS INC.
JOHNSON and JOHNSON
KOWA CO. LTD.
KYORIN PHARMACEUTICAL CO. LTD.
KYOWA HAKKO KIRIN CO. LTD.
LIGAND PHARMACEUTICALS INC.
LG LIFE SCIENCES LTD.
MANNKIND CORP.
MERCK
MERRION PHARMACEUTICALS LTD.
MITSUBISHI TANABE PHARMA CORP.
NEPHROGENEX INC.
NOVARTIS INTERNATIONAL AG
NOVO NORDISK A/S
ONO PHARMACEUTICALS
ORAMED PHARMACEUTICALS
OTSUKA PHARMACEUTICAL CO. LTD.
PFIZER
PHASEBIO PHARMACEUTICALS INC.
QUARK PHARMACEUTICALS INC.
ROCHE
ROYER BIOMEDICAL INC.
SANOFI
SANWA KAGAKU KENKYUSHO CO. LTD.
SATRX LLC
SIHUAN PHARMACEUTICAL HOLDINGS GROUP CO. LTD.
TAKEDA PHARMACEUTICAL CO. LTD.
TRANSITION THERAPEUTICS INC.
TRANSTECH PHARMA LLC
VIKING THERAPEUTICS INC.
ZEALAND PHARMA A/S
ZOSANO PHARMA CORP.

List of Tables

Summary Table : GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, THROUGH 2019
Table 1 : DIFFERENCES BETWEEN THE INCRETIN THERAPIES
Table 2 : ADVANTAGES TO ADDING INCRETIN THERAPY
Table 3 : CURRENT THINKING ON DIABETES MEDICATIONS AND CANCER RISK
Table 4 : COMPLICATIONS/COMORBID CONDITIONS FROM DIABETES
Table 5 : COMMERCIALIZED INCRETIN THERAPY
Table 6 : NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019
Table 7 : MAJOR AGREEMENTS FOR INCRETIN-BASED THERAPY DEVELOPMENT
Table 8 : GLP-1 RECEPTOR AGONISTS IN LATE-STAGE DEVELOPMENT
Table 9 : GLP-1 RECEPTOR AGONISTS IN EARLY-STAGE DEVELOPMENT
Table 10 : DPP-4 INHIBITORS IN LATE-STAGE DEVELOPMENT
Table 11 : DPP-4 INHIBITORS IN EARLY-STAGE DEVELOPMENT
Table 12 : TOP PHARMA COMPANIES BY REVENUE, 2013
Table 13 : BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013
Table 14 : GLOBAL PIPELINE FOR PHASE II AND III STAGE DIABETES MEDICATIONS, THROUGH 2019
Table 15 : GLOBAL PIPELINE FOR PHASE I STAGE DIABETES MEDICATIONS, THROUGH 2019
Table 16 : GLOBAL PIPELINE FOR DIABETES-RELATED DISORDERS, THROUGH 2019
Table 17 : GLOBAL PIPELINE FOR OBESITY, THROUGH 2019
Table 18 : DIABETES AND DRUG DEVELOPMENT RESOURCES

List of Figures

Summary Figure : GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, 2012-2019
Figure 1 : THE INCRETIN EFFECT ILLUSTRATED
Figure 2 : PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR NON-INSULIN ANTIDIABETICS, 2012
Figure 3 : PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012
Figure 4 : PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR DPP-4 INHIBITORS, 2012
Figure 5 : ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014
Figure 6 : NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019
Figure 7 : MARKET SHARE OF INCRETIN-BASED THERAPEUTICS, BY THERAPEUTIC AREA, 2014 AND 2019
Figure 8 : MARKET SHARE OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, BY INCRETIN TYPE, 2014 AND 2019
Figure 9 : MARKET SHARE OF COMMERCIALIZED GLP-1 RECEPTOR AGONISTS, BY DOSING FREQUENCY, 2014 AND 2019
Figure 10 : NUMBER OF INCRETINS IN DEVELOPMENT BY PHASE, 2014
Figure 11 : GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017
Figure 12 : DIABETES-FOCUSED GEOGRAPHIC TERRITORY: NOVO NORDISK SALES, 2013

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.